Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Rao

Showing results (731-740 of 733) with videos related to

Pageof 74
Sort By:
You have reached the last page of results.This site can display upto 733 results.
Oncotarget|October 22, 2021
Correction: Discovery and clinical introduction of first-in-class imipridone ONC201Joshua E Allen, C Leah B Kline, Varun V Prabhu, et al.
Oncotarget|September 8, 2016
Discovery and clinical introduction of first-in-class imipridone ONC201Joshua E Allen, C Leah B Kline, Varun V Prabhu, et al.
Clinical Genitourinary Cancer|December 6, 2016
Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM<sup>SM</sup>Joseph I Clark, Michael K K Wong, Howard L Kaufman, et al.
Pageof 74

Showing results (731-740 of 733) with videos related to

Sort By:
Pageof 74
You have reached the last page of results.This site can display upto 733 results.
Oncotarget|October 22, 2021
Correction: Discovery and clinical introduction of first-in-class imipridone ONC201Joshua E Allen, C Leah B Kline, Varun V Prabhu, et al.
Oncotarget|September 8, 2016
Discovery and clinical introduction of first-in-class imipridone ONC201Joshua E Allen, C Leah B Kline, Varun V Prabhu, et al.
Clinical Genitourinary Cancer|December 6, 2016
Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM<sup>SM</sup>Joseph I Clark, Michael K K Wong, Howard L Kaufman, et al.
Pageof 74